Video Experimental Relacionado
Updated: Jul 26, 2026
09:05
Measurement of Smooth Muscle Function in the Isolated Tissue Bath-applications to Pharmacology Research
Published on: January 19, 2015
Evaluación de un nuevo agente antihipertensivo: clorhidrato de prazosina (Minipress)
JAMA
|July 11, 1977
Resumen
El clorhidrato de prazosina es un nuevo vasodilatador oral para la hipertensión, que causa menos taquicardia que la hidralazina, pero con riesgo de hipotensión en la primera dosis. Su uso está limitado a pacientes intolerantes a otros medicamentos, y debe ser prescrito con un diurético.
Área de la Ciencia:
- Farmacología Farmacología.
- Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.
Sus antecedentes:
- El clorhidrato de prazosina es un vasodilatador administrado por vía oral recientemente aprobado para el tratamiento de la hipertensión.
- Presenta una alternativa a las terapias antihipertensivas existentes.
Objetivo del estudio:
- Evaluar el perfil de eficacia y seguridad del clorhidrato de prazosina en el tratamiento de la hipertensión.
- Para comparar su perfil de efectos secundarios con la hidralazina, particularmente con respecto a la taquicardia y la hipotensión ortostática.
Principales métodos:
- Evaluación clínica de los efectos del clorhidrato de prazosina en la presión arterial y la frecuencia cardíaca.
- Evaluación de los eventos adversos, centrándose en la hipotensión ortostática y las reacciones sincopal.
Principales resultados:
- El clorhidrato de prazosina demuestra propiedades vasodilatadoras con taquicardia reducida en comparación con la hidralazina.
- Un riesgo significativo de hipotensión ortostática, especialmente después de la dosis inicial, limita su papel terapéutico.
- El medicamento está indicado principalmente para pacientes que no pueden tolerar la hidralazina o los fármacos depresores simpáticos.
Conclusiones:
- El clorhidrato de prazosina es una opción viable para la hipertensión, pero su uso requiere una cuidadosa selección del paciente debido al efecto de la primera dosis.
- Se recomienda la administración concomitante con un diurético, similar a otros agentes antihipertensivos.
Videos de Conceptos Relacionados
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...